ImmuNext Inc.
1 Medical Center Drive
Lebanon
New Hampshire
03756
United States
Website: http://immunext.com/
Email: info@ImmuNext.com
About ImmuNext Inc.
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Our lead product, anti-VISTA, is partnered with Janssen for the treatment of cancer and is currently in a Phase I clinical trial. Our second product, VISTA agonists, is partnered with Hoffmann-La Roche for the treatment of autoimmune diseases. Our third product, anti-CD40L, is partnered with Sanofi for the treatment of autoimmune diseases. Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds.YEAR FOUNDED:
2011
LEADERSHIP:
CEO: David DeLucia
CSO: Randolph Noelle
JOBS:
Please click here for ImmuNext job opportunities.
2 articles about ImmuNext Inc.
-
Lilly and ImmuNext Announce Licensing and Research Collaboration
3/26/2019
Eli Lilly and Company and ImmuNext, Inc. announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines for autoimmune diseases by regulating immune cell metabolism.
-
Sanofi, ImmuNext Forge $500 Million Autoimmune Diseases Tie-Up
1/9/2017